Skip to main content

Table 4 Comparative summarized data of patients from the so far largest published case studies for PG between 1985 to 2011[13, 18, 19]

From: Associated factors and comorbidities in patients with pyoderma gangrenosum in Germany: a retrospective multicentric analysis in 259 patients

  Powell et al. (1985) von den Driesch (1997) Bennett et al. (2000) Al Ghazal et al. (2011) Binus et al. (2011) Our data
Patients 86 44 86 49 103 259
Sex (m:w) 1:1 1:2.1 1:1.3 1:1.5 1:3.1 1:1.2
Age (mean) 7-71 yrs. 11-80 yrs. 2-83 yrs. 22-95 yrs. 22-88 yrs. 21-94 yrs.
(n.r.) (50.3 yrs.) (48.4 yrs.) (59.7 yrs.) (51.6 yrs.) (57.3 yrs.)
Pathogenesis - trauma/surgery 23 (27%) 17 (39%) n.r. 16 (33%) 32 (31.1%) 111 (42.8%)
Inflammatory disorders
Arthrosis, non rheumatoid arthritis 28 (33%) n.r. 10 (12%) 1 (2%) 20 (19.4%) 17 (6.6%)
Rheumatoid arthritis n.r. 5 (11%) n.r. 3 (6%) 10 (9.7%) 24 (9.3%)
chronic inflammatory bowel disease 31 (36%) 6 (14%) 18 (21%) 3 (6%) 35 (34%) 24 (9.3%)
Crohn: 14 (16%) Crohn: 3 (7%) Crohn: 8 (9%) Crohn: 1 (2%) Crohn: 17 (16.5%) Crohn: 7 (2.7%)
Ulcerat. col.: 17 (20%) Ulcerat. col.: 3 (7%) Ulcerat. col.: 10 (12%) Ulcerat. col.: 2 (4%) Ulcerat. col: 18 (17.5%) Ulcerat. col.: 17 (6.6%)
Endocrine disorders
Thyreoid disease 5 (6%) n.r. n.r. 7 (14%) 4 (3.9%) 29 (11.2%)
Diabetes mellitus 2 (2%) n.r. n.r. 14 (29%) 29 (28.2%) 66 (25.5%)
Neoplasia
  16 (19%) solid: 5 (6%) 5 (11%) solid: 1 (2%) 8 (9%) solid: n.r. 16 (33%) solid: 6 (12%) 21 (20.4%) solid: n.r. 32 (12.4%) solid: 22 (8.5%)
hematolog.: 11 (13%) hematolog.: 4 (9%) hematolog.: 8 (9%) hematolog: 5 (10%) hematolog.: 21 (20.4%) hematolog.: 10 (3.9%)
solid neoplasms Bladder: 1 (1%) Glioblastoma mult.: 1 (2%) n.r. Breast: 2 (4%) n.r. Breast: 6 (2.3%)
Colon: 2 (2%)    Prostate: 1 (2%)   Lung: 3 (1.2%)
Prostate: 1 (1%)    Melanoma: 2 (4%)   Prostate: 3 (1.2%)
    Glioblastoma mult.: 1 (2%)   Melanoma: 3 (1.2%)
   Liver: 2 (0.8%)
   Ovary: 2 (0.8%)
   Colon: 1 (0.4%)
   Larynx: 1 (0.4%)
   Glioblastoma mult.: 1 (0.4%)
Haematological/haematopoetic neoplasia
AML 1 (1%) n.r. n.r. 0 1 (0.97%) 1 (0.4%)
CLL n.r. 1 (2%) n.r. 0 n.r. 0
CML n.r. 1 (2%) n.r. 2 (4%) n.r. 2 (0.8%)
Other
Myelodysplasia n.r. n.r. 3 (4%) 0 2 (1.9%) 0
Polycythemia rubra vera 1 (1%) n.r. n.r. 0 2 (1.9%) 0
Monoclonal gammopathy 9 (10%) n.r. 4 (5%) 2 (4%) 10 (9.7%) 3 (1.2%)
Plasmocytoma n.r. 1 (2%)   0 1 (1.0%) 2 (0.8%)
POEMS syndrome n.r. n.r. 1 (1%) 0 n.r. 0
Mycosis fungoides/ cutaneous T-cell lymphoma n.r. 1 (2%) n.r. 1 (2%) n.r. 2 (0.8%)
Hodgkin’s lymphoma n.r. n.r. n.r. 0 1 (1.0%) 0
Myelofibrosis n.r. n.r. n.r. 0 1 (1.0%) 0
Large granular lymphocytic leukaemia n.r. n.r. n.r. 0 1 (1.0%) 0
other Non-Hodgkin’s lymphoma n.r. n.r. n.r. 0 1 (1.0%) 0
  1. n. r. = not reported.